Lipocine Inc. 8-K

What Happened

• On May 26, 2026 Lipocine Inc. (LPCN) announced it presented Phase 3 clinical data and a poster for LPCN 1154 (oral brexanolone) at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (May 26–29, 2026) in Miami Beach, FL.
• The presentation highlighted results from Lipocine’s Phase 3 placebo-controlled trial evaluating LPCN 1154 for the treatment of postpartum depression (PPD). The presentation and poster are furnished as Exhibits 99.1 and 99.2 to the Form 8-K.

Key Details

• Date of event: May 26, 2026 (ASCP Annual Meeting running May 26–29, 2026).
• Program: Phase 3, placebo-controlled clinical trial of LPCN 1154 (oral brexanolone) for postpartum depression.
• Filing: Presentation and poster attached to the 8-K as Exhibits 99.1 and 99.2 and incorporated by reference.

Why It Matters

• Phase 3 data are late-stage clinical results that can materially affect a drug’s regulatory path and commercial prospects; presenting these results publicly increases visibility among clinicians, investors, and potential partners.
• The 8-K formalizes the disclosure of those results and makes the presentation materials available to investors for review, which may influence investor assessment of Lipocine’s development progress in PPD.
• The filing does not itself report financial results, regulatory decisions, or definitive outcomes; it documents the presentation of trial data at a major clinical meeting.